Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lung Neoplasms × patritumab deruxtecan × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Neoplasms 2 Esophageal Neoplasms 2 Breast Neoplasms 2 Lung Neoplasms 1 Gastrointestinal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Cancer Metastatic 1

Interventions

pembrolizumab 33 Carboplatin 23 Radiotherapy 21 Paclitaxel 18 Cisplatin 18 Erlotinib Hydrochloride 16 Docetaxel 14 Pemetrexed 12 Nivolumab 11 Gemcitabine 11 osimertinib 10 Etoposide 9 Radiosurgery 8 durvalumab 7 Magnetic Resonance Spectroscopy 7 atezolizumab 6 Specimen Handling 6 Cyclophosphamide 6 Cetuximab 6 Taxes 5 Biopsy 5 Bevacizumab 5 130-nm albumin-bound paclitaxel 5 fludarabine 4 Ipilimumab 4 Immunoglobulin G 4 Gefitinib 4 Albumin-Bound Paclitaxel 4 spartalizumab 3 epacadostat 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07286149 2026-03-16

MK-3475-01F

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡